Survival of advanced CRCs has achieved more than 24 months with the use of new chemotherapeutic agents, especially when combining with molecular targeted drugs.

• 与此同时，新的治疗方法和药物也在不断问世，分子靶向药物是发展最快的一个方向，特别是单克隆抗体与传统的化疗药物的联合已经使得晚期大肠癌患者的生存期超过了24个月。